An update on chronic myeloid leukaemia

Clinical Medicine

Volumn 1, Issue 5, 2001, Pages 354-357

  Stark, Gail ^b   O'Brien, Stephen G ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; HYDROXYUREA; IMATINIB; MACROGOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ALGORITHM; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG MECHANISM; HUMAN; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0034765227     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.1-5-354     Document Type: Review

References (10)

1. Surveillance, epidemiology and end results (SEER) program CD-ROM. National Cancer Institute, DCPC, Surveillance Program. Bethesda, MD: Cancer Statistics Branch, October 1997.
2. Sawyers CL. Chronic myeloid leukemia. Review. N Engl J Med 1999;340:1330-40.
3. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Review. Semin Hematol 1988;25:49-61.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, et al. The biology of chronic myeloid leukemia. Review. N Engl J Med 1999;341: 164-72.
5. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
6. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Review. Blood 1999;94: 1517-36.
7. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997;89:1616-20.
8. Guilhot F, Chastang C, Michallet M, Guerci A, et al. Interferon alfa-2b combined with cytarabine versus Interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-30.
9. McGlave PB, Shu XO, Wen W, Anasetti C, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219-25.
10. Lalancette M, Rezvani K, Szydlo R, Mayer J, et al. Favorable outcome of non-myeloablative stem cell transplant for chronic myeloid leukemia in first chronic phase: a retrospective study of the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood 2000;96: 545a.